Letter from the Editor

Dear colleagues,

Unfortunately, due to COVID-19 restrictions, ECCO (European Crohn’s and Colitis Organisation) 2022 was for the second time an online event.

The theme of this year was “Navigating the Oceans of IBD”, with tantalizing topics such as “Developing environment recipes for IBD”, “Keeping the patient at home: Is telemedicine the future?”, “Aiming high with treatment goals in IBD: The modern Icarus?” and ‘Do we see light at the end of the fistula track”.

Although COVID-19 has had a major impact on our daily lives, the quality of IBD research has not been affected. It is a great honour to present this ECCO 2022 Medicom Conference Report in which we cover amongst others updates on new therapies, head-to-head comparisons and insights into specific therapeutic strategies. I hope you enjoy it and am looking forward to meeting you in person next year in Copenhagen.

Yours, sincerely

Marjolijn Duijvestein

Biography

Dr Marjolijn Duijvestein works as a gastroenterologist in the IBD team of the Radboudumc in Nijmegen, the Netherlands. In 2012 she obtained her PhD at Leiden University and was trained as a gastroenterologist specialised in IBD disease at the Amsterdam UMC in Amsterdam. As part of her training, she gained experience at the University of California San Diego (UCSD, USA) and performed an internship at Alimentiv (former Robarts Clinical Trials), an academic research organisation dedicated to drug development for IBD. Her clinical activity and research are focused on IBD, in particular clinical and translational research.

Conflict of Interest Statement: She has served as an advisor for Echo pharma and Robarts Clinical Trials, reports nonfinancial support from Dr Falk Pharma, and received speaker fees from Janssen, Merck & Co., Pfizer, Takeda and Tillotts Pharma. Advisory boards Janssen, Takeda, BMS and Abbvie.

 



Posted on 12 April 2022